News stories about Checkpoint Therapeutics (NASDAQ:CKPT) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Checkpoint Therapeutics earned a coverage optimism score of 0.02 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 49.9805118805293 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- Mirati Therapeutics’ Mocetinostat Included In Stand Up To Cancer’s Cutting-Edge Clinical Trial Initiative For NSCLC Patients (bizjournals.com)
- Five Prime Therapeutics (FPRX) Says Cabiralizumab Phase 1a/1b Data Abstract Selected for Late Breaking Oral Presentation at SITC (streetinsider.com)
- BRIEF-Checkpoint Therapeutics initiates phase 1 study of antibody CK-301 for metastatic cancers (reuters.com)
- 7 Companies are Having Gaps Down Today – VCEL, IMGN, NPTN, DRAD, MNOV, CKPT, WVFC (fxpips.com)
Checkpoint Therapeutics Company Profile
Checkpoint Therapeutics, Inc is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies.
What are top analysts saying about Checkpoint Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Checkpoint Therapeutics Inc. and related companies.